|
CSL Behring Snags Orphan Designation for Less-Frequently Dosed Hemophilia Drug
The FDA has granted orphan drug status to CSL Behring’s investigational Hemophilia B treatment, a biologic that could allow patients to receive fewer injections to prevent potential bleeding events.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives